ponatinib hydrochloride

Known as: Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1) 
The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
02420112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Over 50 drugs, including anorexigens, abused substances and recently the tyrosine kinase inhibitor (TKI) dasatinib, have been… (More)
Is this relevant?
2015
2015
Ponatinib, an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with chronic myeloid… (More)
Is this relevant?
2014
2014
again without response (bone marrow smear and differential blood counts still showed CP-CML). The third generation TKI ponatinib… (More)
  • table 1
Is this relevant?
2014
2014
Tyrosine kinase inhibitors (TKIs) have profoundly changed the natural history of chronic myeloid leukemia (CML). However… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND In vitro studies have demonstrated that the aqueous solubility of the tyrosine kinase inhibitor ponatinib decreases as… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
PURPOSE The Hedgehog signaling pathway is a key regulator of cell growth and differentiation during development. Whereas the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
BCR-ABL1 compound mutations, defined as ≥2 mutations within the same BCR-ABL1 allele, can confer high-level resistance to… (More)
Is this relevant?
2012
2012
Fms-like tyrosine kinase (FLT3) mutations are the most frequent mutations in patients with acute myeloid leukaemia (AML) that… (More)
Is this relevant?
2012
2012
Impressive response rates and good tolerability have led imatinib 400 mg once a day to become the standard frontline therapy for… (More)
Is this relevant?